NCT03582488View on ClinicalTrials.gov

Longitudinal Imaging Biomarkers of Disease Progression in DLB

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

June 25, 2018

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Lewy Body Disease
Interventions
DRUG

18F-Flortaucipir

Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology

Trial Locations (2)

32224

Mayo Clinic, Jacksonville

55905

Mayo Clinic, Rochester

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Kejal Kantarci

OTHER